172results about "General/multifunctional contrast agents" patented technology

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The present invention relates to a particulate structure comprising: a / biodegradable polymer particles; b / gold nanoparticles whose surfaces are coated with a macrocyclic chelating agent that complexes at least one target ion and / or radionuclide for medical imaging; and c / a polycation that has a positive charge over a pH range of 5 to 11, wherein the gold nanoparticles b / are encapsulated in the polymer particles a / and / or adsorbed to the surface of the polymer particles a / . The present invention also relates to a method for producing the particulate structure. The present invention further relates to the use of the particulate structure for radiotherapy or chemotherapy in cancer treatment.

The application discloses a kind of polypeptide modified long afterglow nano-complex and its preparation method and application, nano-complex, for core-shell structure, core-shell structure is composed of the core body in inside and the shell that surrounds core body, core body is long afterglow nanomaterial, shell is by polypeptide modification and modified molecule modification, and drug loaded dendritic polymer;The nano-complex of the application can realize multiscale imaging to osteoclast, through in vivo afterglow imaging and in vivo two-photon microscopic imaging, the morphology, migration and distribution of osteoclast can be more accurately analyzed, avoid photo toxicity and background interference, improve imaging sensitivity;The nano-complex of the application is loaded with osteoporosis treatment drug alendronate ALN, and treatment drug can be replaced according to actual demand, and treatment scheme is adjusted, so that the drug loading system has universality.

A logic-gated protein device in which proximity-gated protein trans-splicing governs formation of an active protein from two otherwise inactive fragments.

The present invention relates to multivalent and multispecific nanoparticle platforms and methods. A fusion protein comprising: a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety attached to the first nanocage monomeric subunit; wherein the fusion protein is self-assembled with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

The application belongs to the technical field of material preparation, and relates to a bimodal functional imaging nanomaterial and a preparation method and application thereof. 1‑x Fe x Se2, wherein 0 < x < 1. The preparation method of the bimodal functional imaging nanomaterial comprises the following steps: stirring ferrous sulfate and cysteine in a solvent until uniform, then fully stirring bismuth salt, then adding sodium selenite to perform a heating reaction to obtain a bismuth iron selenium nanocomposite. The bismuth iron selenium nanocomposite provided by the application is uniform in size, regular in morphology, has good water phase dispersibility, and has the performance of simultaneously enhancing MRI imaging and CT imaging.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

The present invention relates to a compound of the following formula (A) for use mainly as a radiopaque monomer. The present invention further relates to radiopaque embolization microspheres based on at least 20% - 90% hydrophilic monomer, 5% - 50% compound of formula (A), 1% - 15% non - biodegradable hydrophilic cross - linking monomer, and - 0.1% - 10% migrating agent. The present invention also relates to a pharmaceutical composition comprising at least one embolization microsphere according to the invention, preferably with a pharmaceutically acceptable carrier for parenteral administration. The present invention further relates to a kit comprising a pharmaceutical composition according to the invention with a pharmaceutically acceptable carrier for parenteral administration and injection means. TIFF2025521863000019.tif20128

An antibody, or an antigen-binding fragment of same, specifically binding to a BCMA, a nucleic acid encoding same, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in treating a disease, for example, the use thereof in treating a tumour.

Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.

The invention discloses a manganese phenol network coated polyethyleneimine stabilized polypyrrole nanoparticle and application thereof, and belongs to the technical field of biological medicine. Hyperbranched polyethyleneimine is used as a carrier, polypyrrole and Mn < 2 + > are integrated in a functionalized PEI.NH2 nano system, PPy nanoparticles are stabilized through the functionalized PEI.NH2, then gold nanoparticles are wrapped in the functionalized PEI.NH2, and finally the nano composite system is wrapped with a tannic acid-manganese ion network through a one-step assembly method. The preparation method comprises the following steps: constructing a PEI.NH2 stable PPy nanoparticle Au-PPy PPSNs (at) TMn coated with a manganese phenol network; according to the Au-PPy PPSNs (at) TMn disclosed by the invention, CDT / PTT synergistic treatment and CT / MR (Computed Tomography / Magnetic Resonance) bimodal imaging of cancer cells can be realized.

The invention relates to a breast cancer diagnosis probe, in particular to a fluorescence / magnetic resonance enhanced bimodal breast cancer imaging polypeptide probe as well as a preparation method and application thereof. The polypeptide probe is prepared from a fluorescence imaging unit, a magnetic resonance imaging unit, a self-assembly imaging unit and a TROP-2 targeted recognition unit. According to the invention, the polypeptide probe for enhancing fluorescence / magnetic resonance signals through in-situ self-assembly is constructed, and the polypeptide probe synthesized through modular optimization can realize in-situ self-assembly mediated by high-expression TROP-2 protein of triple negative breast cancer cells; self-assembly along with fluorescence and magnetic resonance unit aggregation can significantly enhance fluorescence and magnetic resonance bimodal imaging signals of triple-negative breast cancer tissues, improve imaging sensitivity and enhance triple-negative breast cancer imaging effects.

The present invention discloses a multi-substrate adhesive hydrogel capable of efficiently delivering nucleic acid molecules and its application in tumor treatment. The preparation steps of the hydrogel are as follows: preparing a MXene nanosheet solution by hydrofluoric acid etching; preparing a disulfide solid powder by recrystallization; mixing the disulfide solid powder with the MXene nanosheet solution and stirring at room temperature to obtain solution A; mixing CpG oligonucleotide with solution A and dialyzing to obtain an ONMs nanoparticle solution; grafting sodium alginate and amino-modified ATP aptamer to obtain DNA SA solution; ONMs nanoparticle solution and DNA SA solution was mixed and incubated at room temperature to obtain DNA SA@ONMs solution; DNA The SA@ONMs solution was mixed with acrylamide, and then an ionic crosslinker, a crosslinker, a crosslinking accelerator, and an initiator were added in sequence. The mixture was stirred at room temperature and allowed to stand to solidify into a gel, thereby obtaining a multi-substrate adhesion hydrogel.

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and / or therapy.The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRD and / or in other diagnostic techniques and / or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.Thus, the nanoparticles according to the invention, with diameter d1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein).The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

The invention discloses an A-D-A type NIR-II multi-mode optical diagnosis and treatment agent with multi-mode imaging guiding and photodynamic-photo-thermal synergistic treatment functions as well as a preparation method and application of the NIR-II multi-mode optical diagnosis and treatment agent. The NIR-II multi-mode optical diagnosis and treatment agent comprises a compound as shown in a structural formula I, or pharmaceutically acceptable salt, solvate and tautomer of the compound. According to the NIR-II multi-mode light diagnosis and treatment material, multi-mode imaging guidance and the photo-thermal-photodynamic effect are combined, many limitations in the prior art can be overcome, efficient diagnosis and treatment of diseases such as tumors and inflammation are achieved, and then development of the multi-mode diagnosis and treatment technology is promoted.

The application provides a kind of dual-mode acoustic contrast agent with targeting and its preparation method and application, belong to the technical field of ultrasound contrast agent preparation. By compounding ultrasound contrast agent and fluorescent particles, a dual-mode acoustic contrast agent including ultrasound contrast agent and fluorescent probe containing DBCO structure is formed. The dual-mode acoustic contrast agent has targeting, and the DBCO group on the surface of the fluorescent probe can react with Ac4ManNAz to form an azide group enriched in tumor tissue, thereby realizing significant targeted fluorescence imaging of tumors, which is beneficial to early detection of tumors. The dual-mode acoustic contrast agent has both ultrasound imaging and targeted fluorescence imaging functions, with high imaging sensitivity and strong specificity, and has good application prospect.

A programmed cell death ligand 1 (PD-L1) targeting polypeptide, a molecular imaging probe, and a use thereof are provided. The PD-L1 targeting polypeptide includes any one of the following polypeptides: (1) a polypeptide shown in at least one of SEQ ID NO: 1 to SEQ ID NO: 9; and (2) a polypeptide that is derived from an amino acid sequence of (1) through a substitution and / or a deletion and / or an addition of one or more amino acid residues and has the same function as the amino acid sequence. The magnetic resonance molecular imaging probe based on the PD-L1 targeting polypeptide enables the early diagnosis and evaluation of a tumor and an immune-mediated myocardial injury.

The invention relates to preparation and application of a malignant tumor targeting gambogic acid preparation. An inner core-middle layer-shell three-layer structure is adopted, wherein the inner core is a gambogic acid-black phosphorus quantum dot compound and has chemical treatment and photo-thermal treatment functions; the middle layer is nano vesicles derived from frozen NK92 MI cells and provides natural immune targeting and killing ability; a shell is a hyaluronic acid chelate, and active targeting and pH / photo-thermal response type drug controlled release are achieved. The core of the preparation method is that a coaxial electrojet technology is adopted, three layers of materials are formed in one step, the process is efficient, and the preparation stability is good. The preparation can realize photo-thermal-chemical-immune triple synergistic treatment, has near-infrared fluorescence and photo-acoustic multimode imaging functions, effectively solves the problems of poor targeting property, large toxic and side effects and lack of real-time monitoring of traditional chemotherapy, and shows significant advantages and application potential in precise treatment and diagnosis of solid tumors.

To provide a preparation method and the use of a nanocarrier especially a liposome delivery system, in the diagnosis, prevention and treatment of a vulnerable plaque or a disease associated with the vulnerable plaque.SOLUTION: The present invention provides a liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.SELECTED DRAWING: None

Described herein are methods for imaging magnetic resonance imaging (MRI) agents containing nanoconstructs therein using diffusion weighted fast spin echo (FSE) or gradient and spin echo (GRASE) methods.

The present invention relates to molecules having a soluble tag and methods for increasing the solubility of molecules. Additionally, the present invention relates to antibody-drug conjugates having a soluble tag, methods and compounds for preparing such antibody-drug conjugates, methods for increasing the solubility of antibody-drug conjugates, antibody-drug conjugates prepared by such methods, and the use of such antibody-drug conjugates in medicine.

The invention discloses a Fe (III)-EGCG (epigallocatechin gallate) network coated copper sulfide nano-composite and application thereof, and belongs to the technical field of biological medicines. Polyethyleneimine is used as a nano-carrier, PEG-FA and FI are modified on the surface of the nano-carrier, CuS NPs is synthesized in situ in an internal cavity of the nano-carrier, residual amino groups on the surface of PEI.NH2 are functionalized through acetylation, and finally, FA-CuS PENs are coated with a metal polyphenol network Fe-EGCG, so that the nano-carrier is obtained. The Fe (III)-EGCG network coated copper sulfide nano-composite with the cancer cell MR imaging and chemical / photo-thermal / chemical kinetics combined treatment function is constructed. The nano-composite disclosed by the invention can realize high-amount uptake of cancer cells highly expressed by an FA receptor, and further realizes targeted cancer cell MR imaging and chemical / photo-thermal / chemical kinetics combined therapy.

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

Disclosed are methods of imaging a cancer cell, the method comprising applying a first alternating electric field at a first frequency to the cancer cell for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cell for the first period of time increases permeability of cell membranes of the cancer cell; introducing a nanoparticle to the cancer cell, wherein the increased permeability of the cell membranes enables the nanoparticle to cross the cancer cell membrane; and imaging the cancer cell.

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.

The application discloses a protein anchoring type copper response photoacoustic probe and a preparation method and application thereof, the probe can be selectively chelated with copper in the mitochondria of tumor cells, so that the photoacoustic signal of the probe is activated, in-situ tracing and quantification of copper ions in the tumor are realized. Meanwhile, copper chelation realizes copper depletion in the mitochondria, causes damage to the structure and function of the mitochondria, and realizes diagnosis and treatment integration of the tumor. In addition, the probe can specifically react with protein sulfenic acid in the mitochondria to form a probe-protein conjugate, promote enrichment of the probe at the tumor site, prolong the imaging window and improve the treatment effect of copper depletion.